Publication | Open Access

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Hematological MalignancyLymphoid NeoplasiaMedicineImmunologyClinical TrialsHematologyPrimary AnalysisImmune Checkpoint InhibitorAdult T-cell Leukemia-lymphomaImmunotherapyOncologyRadiation OncologyHealth Sciences